Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies - PubMed (original) (raw)

Review

Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies

Jacob S Thomas et al. Crit Rev Oncol Hematol. 2015 Dec.

Abstract

Treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically in the past 10 years, largely due to advances in understanding of tumor biology. A number of targeted therapies have been shown to improve progression free survival and overall survival as compared to nonspecific immunotherapy. Despite the success of targeted therapies, they have not produced durable responses that have been seen historically with immunotherapy such as IL-2 (interleukin 2) and IFN-α (interferon). The promise of durable responses has caused some to shift research focus from targeted therapies to novel immunotherapies. This article reviews the literature behind the current targeted therapies and describes several novel approaches to immunotherapy that are in various phases of development.

Keywords: Carcinoma; Dendritic cells; Immunotherapy; Programmed cell death 1 receptor; Renal cell.

PubMed Disclaimer

Cited by

The Role of Long Noncoding RNA (lncRNAs) Biomarkers in Renal Cell Carcinoma.
Rysz J, Konecki T, Franczyk B, Ławiński J, Gluba-Brzózka A. Rysz J, et al. Int J Mol Sci. 2022 Dec 30;24(1):643. doi: 10.3390/ijms24010643. Int J Mol Sci. 2022. PMID: 36614082 Free PMC article. Review.
Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: a systematic review and meta-analysis.
Xu Y, Zhang Y, Wang X, Kang J, Liu X. Xu Y, et al. BMC Cancer. 2019 Feb 22;19(1):168. doi: 10.1186/s12885-019-5375-0. BMC Cancer. 2019. PMID: 30795756 Free PMC article.
MiR-200c-3p inhibits cell migration and invasion of clear cell renal cell carcinoma via regulating SLC6A1.
Maolakuerban N, Azhati B, Tusong H, Abula A, Yasheng A, Xireyazidan A. Maolakuerban N, et al. Cancer Biol Ther. 2018 Apr 3;19(4):282-291. doi: 10.1080/15384047.2017.1394551. Epub 2018 Feb 2. Cancer Biol Ther. 2018. PMID: 29394133 Free PMC article.
Hub Long Noncoding RNAs with m6A Modification for Signatures and Prognostic Values in Kidney Renal Clear Cell Carcinoma.
Lin G, Wang H, Wu Y, Wang K, Li G. Lin G, et al. Front Mol Biosci. 2021 Jul 6;8:682471. doi: 10.3389/fmolb.2021.682471. eCollection 2021. Front Mol Biosci. 2021. PMID: 34295922 Free PMC article.
The kidney cancer research priority-setting partnership: Identifying the top 10 research priorities as defined by patients, caregivers, and expert clinicians.
Jones J, Bhatt J, Avery J, Laupacis A, Cowan K, Basappa N, Basiuk J, Canil C, Al-Asaaed S, Heng D, Wood L, Stacey D, Kollmannsberger C, Jewett MAS. Jones J, et al. Can Urol Assoc J. 2017 Dec;11(12):379-387. doi: 10.5489/cuaj.4590. Epub 2017 Nov 1. Can Urol Assoc J. 2017. PMID: 29106364 Free PMC article.

Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies - PubMed (original) (raw)